Efficacy and safety analysis of domestic dasatinib as second-line treatment for pediatric adolescents with chronic myeloid leukemia in chronic phase
-
摘要: 目的 探讨国产达沙替尼二线治疗慢性髓系白血病(chronic myeloid leukemia，CML)慢性期儿童青少年患者的疗效及安全性。方法 回顾性分析2016年8月至2021年9月我院收治的国产达沙替尼二线治疗CML慢性期儿童青少年患者的病例资料，统计治疗3、6、12个月时最佳反应率、累积完全细胞遗传学反应率、累积主要分子学反应率、无进展生存率、无事件生存率及不良反应发生情况。结果 共纳入29例患者，中位随访时间为26(12~75)个月，治疗3、6、12个月时最佳反应率分别为82.8%(24/29)、93.1%(27/29)、86.2%(25/29)，至随访截止时间，累积完全细胞遗传学反应率、累积主要分子学反应率分别为86.2%(25/29)和65.5%(19/29)。随访时间内，无进展生存率为100.0%(29/29)，无事件生存率为82.8%(24/29)。最常见的非血液学不良反应为肝酶升高(10.3%)、皮疹(10.3%)，血液学不良反应主要有贫血(24.1%)、血小板减少(6.9%)。结论 国产达沙替尼二线治疗CML慢性期儿童青少年患者具有较好的疗效与安全性，可作为CML慢性期儿童青少年患者的二线用药选择之一。Abstract: Objective To investigate the efficacy and safety of domestic dasatinib as second-line treatment for pediatric adolescents with chronic myeloid leukemia in chronic phase(CML-CP).Methods A retrospective analysis of clinical data of CML-CP pediatric adolescents who received domestic dasatinib as second-line treatment in the Henan Tumor Hospital from August 2016 to September 2021 was performed. The optimal response rate at 3, 6 and 12 months, the cumulative rates of complete cytogenetic response and major molecular responses, the rates of progression free survival and event free survival, adverse events of the patients were assessed.Results A total of 29 patients were enrolled in this study. The median follow-up time was 26(12-75) months. The optimal response rates at 3, 6 and 12 months were 82.8%(24/29), 93.1%(27/29), 86.2%(25/29), respectively. By the end of follow-up, the cumulative rates of complete cytogenetic response and major molecular response were 86.2%(25/29) and 65.5%(19/29), respectively. During follow-up, the rates of progression free survival and event free survival were 100.0%(29/29) and 82.8%(24/29), respectively. The most common non-hematological adverse events of dasatinib were elevated transaminase level(10.3%) and rash(10.3%). The common hematological adverse events of dasatinib were anemia(24.1%) and thrombocytopenia(6.9%).Conclusion Domestic dasatinib is effective and safe as the second-line treatment of CML-CP pediatric adolescents and can be a good choice.
-
Key words:
- chronic myeloid leukemia /
- dasatinib /
- efficacy /
- safety
-
-
[1] Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv41-iv51.
[2] 黎纬明, 余甜. 慢性髓系白血病合并传染病的规范化管理进展[J]. 临床血液学杂志, 2023, 36(5): 316-320. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2023.05.004
[3] Radich JP, Deininger M, Abboud CN, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16(9): 1108-1135. doi: 10.6004/jnccn.2018.0071
[4] Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia[J]. N Engl J Med, 2017, 376(10): 917-927. doi: 10.1056/NEJMoa1609324
[5] 邓梦月. 儿童慢性粒细胞白血病的酪氨酸激酶抑制剂治疗进展[J]. 儿科药学杂志, 2021, 27(2): 55-59. https://www.cnki.com.cn/Article/CJFDTOTAL-EKYX202102017.htm
[6] 中华医学会血液学分会. 慢性髓性白血病中国诊断与治疗指南(2020年版)[J]. 中华血液学杂志, 2020, 41(5): 353-364.
[7] Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood, 2013, 122(6): 872-884. doi: 10.1182/blood-2013-05-501569
[8] Pulte D, Gondos A, Brenner H, et al. Trends in survival after diagnosiswith hematologic malignancy in adolescence or young adulthood inthe United States, 1981-2005[J]. Cancer, 2009, 115(21): 4973-4979. doi: 10.1002/cncr.24548
[9] Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach[J]. Blood, 2016, 127(4): 392-399. doi: 10.1182/blood-2015-06-648667
[10] 中国医师协会血液科医师分会, 中华医学会儿科学分会血液学组. 儿童慢性髓细胞性白血病诊疗专家共识[J]. 中华儿科杂志, 2022, 60(10): 967-969.
[11] Andolina JR, Burke MJ, Hijiya N, et al. Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia[J]. Biol Blood Marrow Transplant, 2019, 25(2): 321-327. doi: 10.1016/j.bbmt.2018.09.029
[12] Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents[J]. Blood, 2019, 133(22): 2374-2384. doi: 10.1182/blood.2018882233
[13] Suttorp M, Schulze P, Glauche I, et al. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase Ⅲ trial[J]. Leukemia, 2018, 32(7): 1657-1669. doi: 10.1038/s41375-018-0179-9
[14] Giona F, Putti MC, Micalizzi C, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience[J]. Br J Haematol, 2015, 170(3): 398-407. doi: 10.1111/bjh.13453
[15] Cai Y, Liu C, Guo Y, et al. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China[J]. Int J Hematol, 2021, 113(3): 413-421. doi: 10.1007/s12185-020-03042-1
[16] Dou X, Zheng F, Zhang L, et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study[J]. Ann Hematol, 2021, 100(9): 2215-2228. doi: 10.1007/s00277-021-04544-6
[17] Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood, 2013, 122(6): 872-884. doi: 10.1182/blood-2013-05-501569
[18] 黄晓军, 胡建达, 李建勇, 等. 达沙替尼对中国慢性髓性白血病伊马替尼耐药或不耐受患者疗效及安全性研究[J]. 中华血液学杂志, 2012, 33(11): 889-895. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201613016.htm
[19] Shah NP, Rousselot P, Schiffer C, et al. dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034[J]. Am J Hematol, 2016, 91(9): 869-874. doi: 10.1002/ajh.24423
[20] 陈怡琳, 王龙, 袁国林, 等. 国产达沙替尼二线治疗慢性髓性白血病慢性期患者的疗效和安全性分析[J]. 中华血液学杂志, 2019, 40(2): 98-104.
[21] Gore L, Kearns PR, de Martino ML, et al. dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase Ⅱ Trial[J]. J Clin Oncol, 2018, 36(13): 1330-1338. doi: 10.1200/JCO.2017.75.9597
[22] Hijiya N, Maschan A, Rizzari C, et al. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia[J]. Blood, 2019, 134(23): 2036-2045. doi: 10.1182/blood.2019000069
[23] Nickel RS, Daves M, Keller F, et al. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib[J]. Pediatr Blood Cancer, 2015, 62(11): 2050-2051. doi: 10.1002/pbc.25551
[24] 韩默君, 张龑莉, 祖璎玲, 等. 达沙替尼二线治疗儿童慢性髓性白血病临床分析[J]. 肿瘤学杂志, 2020, 26(8): 745-748. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON202008018.htm
-
计量
- 文章访问数: 1324
- PDF下载数: 361
- 施引文献: 0
下载: